

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY,
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,
Patent Owner.

CASE IPR2018-01426
Patent 9,890,211

PATENT OWNER'S SURREPLY

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	Introduction.....	1
II.	Lilly premised its case on the “therapeutic utility” of anti-CGRP antibodies; it should be held to this rationale.	3
III.	Lilly’s new “ <i>potential</i> therapeutic” rationale fails the obviousness inquiry.....	5
	A. The record does not demonstrate that a full-length anti-CGRP antibody would have been reasonably expected to be effective <i>in vivo</i>	6
	B. Lilly failed to demonstrate that humanized anti-CGRP antibodies would have been safe in humans.	10
	1. Lilly improperly ignores myriad teachings showing CGRP’s vasoprotective role.....	11
	2. Risk concerns of antagonizing CGRP with long-acting antibodies were not “theoretical.”	11
	3. Any alleged safety of blocking the CGRP pathway with small molecules, receptor antagonists, or aptamers is irrelevant to the safety of anti-CGRP antibodies.	13
	4. Lilly improperly dismisses safety concerns with antagonizing CGRP in migraineurs.	19
IV.	Lilly’s motivation arguments fail to consider pharmacological differences between receptor and ligand antagonism.....	21
V.	Lilly failed to prove that a POSA would have arrived at the claimed affinity (K_D).	24
VI.	Lilly never articulated which prior art antibody a POSA would have humanized in order to arrive at the claimed antibodies.....	24
VII.	Lilly misreads Teva’s secondary indicia arguments and has not rebutted the presumption of nexus.....	25
VIII.	Conclusion.....	28

I. Introduction

Teva's Patent Owner Response ("POR") exposed multiple infirmities that defeat Lilly's obviousness case. Teva demonstrated that Lilly's principal references—Tan 1995 and Wimalawansa—would not have motivated a POSA to develop an anti-CGRP antibody for human therapeutic use. Tan 1995, a basic research paper attempting to “prob[e] the role of CGRP as an endogenous vasodilator” in rats, reported that its full-length anti-CGRP antibody failed to show immunoblockade in a rat saphenous nerve assay. Wimalawansa—far from suggesting humanizing anti-CGRP antibodies, as Lilly argues—expressly conveys to a POSA that “[c]learly, more data from carefully designed studies are necessary before ... humanized anti-CGRP monoclonal antibodies ... can be evaluated as therapeutic agents.” And Lilly has not shown that such data existed prior to 2005.

Unable to overcome these and other fatal defects, Lilly accuses Teva of “impermissibly reading safety and efficacy requirements into the claims.” But it was Lilly who premised its Petition on *human therapeutic use*. Teva rebutted Lilly's arguments by, *inter alia*, showing that Lilly failed to consider *safety*, and fell short of demonstrating *efficacy*.

Rather than considering the prior art as a whole, as it must, Lilly, through hindsight, selectively cherry-picks references Lilly believes support its arguments, while ignoring references that undermine them. Even worse, on cross-examination

Dr. Charles and his replacement, Dr. Balthasar¹, distanced themselves from unfavorable portions of Lilly's *own* references upon which they themselves relied. Specifically, these experts refused to consider teachings that call into question the safety of long-term (as with an antibody) inhibition of CGRP, the body's most potent vasodilator. Given that Lilly constructed its obviousness case on a therapeutic utility, the lack of safety and efficacy in its evidence cannot be ignored.

On Reply, Lilly now pivots from its initial "human therapeutic use" arguments, focusing instead on the mere "potential" for therapeutic use. But Lilly cannot re-craft its challenge on Reply to attempt to rehabilitate its Petition. *Henny Penny Corp. v. Frymaster LLC*, No. 18-1596 (Fed. Cir. 2019).

To support its new rationale, Lilly again cherry-picks isolated, out-of-context phrases to repaint the field as of 2005. For example, to support the alleged *in vivo* effectiveness of Tan's C4.19 antibody, Lilly cites to Teva's Dr. Ferrari. But Dr. Ferrari's testimony referred to Tan's Fab' fragment, not full-length C4.19. And Lilly's new arguments that carcass studies support speculation that Tan's antibody would eventually reach its site of action given more time also fail because

¹ Teva discredited a number of Dr. Charles' opinions, and showed him to be unqualified to offer them. POR, 3-4. On Reply, Lilly submitted the declaration of a new expert Dr. Balthasar in an effort to repair Dr. Charles' failed opinions.

“*assignment of a site* ... of antibody localization *was not possible*.”²

Similarly, Lilly’s speculation about “increased dose” goes squarely against safety concerns regarding long-term CGRP ligand antagonism, which would remove CGRP’s protective role during ischemic events, where the risk of stroke and heart attacks are elevated. This is important because migraineurs were known to have increased risk of these life-threatening conditions.

Lilly also fails to rebut Teva’s strong showing of numerous indicia of non-obviousness, which support confirming the challenged claims. In short, Teva’s Response demonstrates that Lilly’s Petition fails to show that the claimed humanized antibodies would have been obvious. Lilly’s Reply does not salvage its Petition.

II. Lilly premised its case on the “therapeutic utility” of anti-CGRP antibodies; it should be held to this rationale.

Lilly provided only one reason for developing a humanized anti-CGRP antibody: human therapeutic use. Petition, 12-13, 25-28, 32-33. Lilly specifically argued the reason for humanizing a murine antibody was to retain “the antibody’s therapeutic utility” “in humans.” *Id.*, 32-33. By doing so, Lilly (not Teva) read “safety and efficacy requirements into the claims.” Under a similar challenge to composition of matter claims, as here, the Board held the petitioner to its

² Emphasis added throughout unless otherwise noted.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.